文献速递糖尿病

1型糖尿病成人全国报销间歇扫描式持续葡萄糖监测1年后的生活质量和血糖控制(FUTURE):一项前瞻性观察性真实世界队列研究

Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study.
PubMed 文献 · Diabetes Care · 2019-12-16

比利时2016年起对专科中心治疗的1型糖尿病成人全国报销间歇扫描式持续葡萄糖监测(isCGM),本研究在2016年7月至2018年7月连续纳入1,913例成人开展12个月前瞻性观察性多中心真实世界研究。结果显示治疗满意度改善,严重低血糖和/或酮症酸中毒住院减少,严重低血糖事件和低血糖昏迷报告减少,工作缺勤减少,HbA1c维持不变,生活质量稳定;低血糖时间显著减少但范围内时间减少、高血糖时间增加。

要点

  • 全国报销isCGM后1年治疗满意度改善(P<0.0001),生活质量和HbA1c维持稳定。
  • 严重低血糖和/或酮症酸中毒住院从3.3%降至2.2%(P=0.031)。
  • 严重低血糖事件从14.6%降至7.8%,低血糖昏迷从2.7%降至1.1%,工作缺勤从5.8%降至2.9%。

核心结论

  • 在专科糖尿病中心治疗的1型糖尿病患者中,全国无限制报销isCGM带来更高的治疗满意度、更少的严重低血糖和更少的工作缺勤,同时生活质量和HbA1c维持不变。

研究设计与样本

  • 2016年7月至2018年7月在三个专科糖尿病中心连续纳入1,913例1型糖尿病成人,开展为期12个月的前瞻性观察性多中心真实世界研究。
  • 在基线、6个月和12个月标准化临床随访时收集人口学、代谢和生活质量数据;主要终点为基线至12个月生活质量的变化。

主要发现

  • 基线和糖尿病特异性生活质量高且保持稳定,治疗满意度改善(P<0.0001)。
  • 研究前一年严重低血糖和/或酮症酸中毒住院为3.3%(1,913例中63例),研究期间降至2.2%(1,711例中37例;P=0.031)。
  • 研究期间报告严重低血糖事件者从14.6%(1,913例中280例)降至7.8%(1,711例中134例;P<0.0001),低血糖昏迷从2.7%(1,913例中52例)降至1.1%(1,711例中18例;P=0.001),HbA1c水平维持不变。
  • 工作缺勤者从5.8%(1,913例中111例)降至2.9%(1,711例中49例;P<0.0001)。
  • 低血糖时间显著减少,同时范围内时间减少、高血糖时间增加;11%(210例)参与者出现皮肤反应,22例(1%)因此停止isCGM。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2016, nationwide reimbursement of intermittently scanned continuous glucose monitoring (isCGM) for people living with type 1 diabetes treated in specialist diabetes centers was introduced in Belgium. We undertook a 12-month prospective observational multicenter real-world study to investigate impact of isCGM on quality of life and glycemic control. RESEARCH DESIGN AND METHODS: Between July 2016 and July 2018, 1,913 adults with type 1 diabetes were consecutively recruited in three specialist diabetes centers. Demographic, metabolic, and quality of life data were collected at baseline, 6 months, and 12 months of standardized clinical follow-up. The primary end point was evolution of quality of life from baseline to 12 months. Secondary outcome measures were, among others, change in HbA1c, time spent in different glycemic ranges, occurrence of acute diabetes complications, and work absenteeism. RESULTS: General and diabetes-specific quality of life was high at baseline and remained stable, whereas treatment satisfaction improved (P < 0.0001). Admissions for severe hypoglycemia and/or ketoacidosis were rare in the year before study (n = 63 out of 1,913; 3.3%), but decreased further to 2.2% (n = 37 out of 1,711; P = 0.031). During the study, fewer people reported severe hypoglycemic events (n = 280 out of 1,913 [14.6%] vs. n = 134 out of 1,711 [7.8%]; P < 0.0001) or hypoglycemic comas (n = 52 out of 1,913 [2.7%] vs. n = 18 out of 1,711 [1.1%]; P = 0.001) while maintaining HbA1c levels. Fewer people were absent from work (n = 111 out of 1,913 [5.8%] vs. n = 49 out of 1,711 [2.9%]; P < 0.0001). Time spent in hypoglycemia significantly decreased in parallel with less time in range and more time in hyperglycemia. Eleven percent (n = 210) of participants experienced skin reactions, leading to stopping of isCGM in 22 participants (1%). CONCLUSIONS: Nationwide unrestricted reimbursement of isCGM in people with type 1 diabetes treated in specialist diabetes centers results in higher treatment satisfaction, less severe hypoglycemia, and less work absenteeism, while maintaining quality of life and HbA1c.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Charleer S, De Block C, Van Huffel L, et al. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care. 2019. PMID: 31843948. doi:10.2337/dc19-1610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。